These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9604055)

  • 1. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.
    Lems WF; Jacobs WG; Bijlsma JW; Croone A; Haanen HC; Houben HH; Gerrits MI; van Rijn HJ
    Osteoporos Int; 1997; 7(6):575-82. PubMed ID: 9604055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
    Lems WF; Jacobs JW; Bijlsma JW; van Veen GJ; Houben HH; Haanen HC; Gerrits MI; van Rijn HJ
    Ann Rheum Dis; 1997 Jun; 56(6):357-63. PubMed ID: 9227164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
    Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
    Pak CY; Adams-Huet B; Sakhaee K; Bell NH; Licata A; Johnston C; Rubin B; Bonnick S; Piziak V; Graham H; Ballard J; Berger R; Fears W; Breslau N; Rubin C
    J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
    Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
    Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
    Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis.
    Riggs BL; O'Fallon WM; Lane A; Hodgson SF; Wahner HW; Muhs J; Chao E; Melton LJ
    J Bone Miner Res; 1994 Feb; 9(2):265-75. PubMed ID: 8140940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium fluoride prevents bone loss in primary biliary cirrhosis.
    Guañabens N; Parés A; del Rio L; Roca M; Gómez R; Muñoz J; Rodés J
    J Hepatol; 1992 Jul; 15(3):345-9. PubMed ID: 1447501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
    Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
    Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
    Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.
    Nagant de Deuxchaisnes C; Devogelaer JP; Depresseux G; Malghem J; Maldague B
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S5-26. PubMed ID: 2187327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.
    Healey JH; Paget SA; Williams-Russo P; Szatrowski TP; Schneider R; Spiera H; Mitnick H; Ales K; Schwartzberg P
    Calcif Tissue Int; 1996 Feb; 58(2):73-80. PubMed ID: 8998681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.
    Adachi JD; Bensen WG; Bianchi F; Cividino A; Pillersdorf S; Sebaldt RJ; Tugwell P; Gordon M; Steele M; Webber C; Goldsmith CH
    J Rheumatol; 1996 Jun; 23(6):995-1000. PubMed ID: 8782129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.